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Purpose: To assess the levels of quality of life (QoL) in major depressive disorder (MDD) 
patients treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI) as 
monotherapy for up to 6 months in a naturalistic clinical setting mostly in the Middle East, 
East Asia, and Mexico.
Patients and methods: Data for this post hoc analysis were taken from a 6-month prospective 
observational study involving 1,549 MDD patients without sexual dysfunction. QoL was measured 
using the EQ-5D instrument. Depression severity was measured using the Clinical Global Impres-
sion of Severity and the 16-item Quick Inventory of Depressive Symptomatology Self-Report 
(QIDS-SR
16
), while pain severity was measured using the pain items of the Somatic Symptom 
Inventory. Regression analyses were performed to compare the levels of QoL between duloxetine-
treated (n=556) and SSRI-treated (n=776) patients, adjusting for baseline patient characteristics.
Results: These MDD patients, on average, had moderately impaired QoL at baseline, and the 
level of QoL impairment was similar between the duloxetine and SSRI groups (EQ-5D score 
of 0.46 [SD =0.32] in the former and 0.47 [SD =0.33] in the latter, P=0.066). Both descriptive 
and regression analyses confirmed QoL improvements in both groups during follow-up, but 
duloxetine-treated patients achieved higher QoL. At 24 weeks, the estimated mean EQ-5D 
score was 0.90 in the duloxetine cohort, which was statistically significantly higher than that 
of 0.83 in the SSRI cohort (P0.001). Notably, pain severity at baseline was also statistically 
significantly associated with poorer QoL during follow-up (P0.001). In addition, this asso-
ciation was observed in the subgroup of SSRI-treated patients (P0.001), but not in that of 
duloxetine-treated patients (P=0.479).
Conclusion: Depressed patients treated with duloxetine achieved higher QoL, compared to 
those treated with SSRIs, possibly in part due to its moderating effect on the link between pain 
and poorer QoL.
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Introduction
Major depressive disorder (MDD) is a highly prevalent mental disorder that is associated 
with significant levels of disability, morbidity, and mortality. It is one of the leading 
causes of disability globally, affecting nearly 350 million people worldwide,1 and the 
burden associated with MDD continues to increase.2 The 2010 Global Burden of Disease 
Study, for instance, showed a 37% increase in disability-adjusted life years due to MDD 
between 1990 and 2010.2 MDD is also known to have a major impact on health-related 
quality of life (QoL) and functioning. For example, a previous study by Rapaport et al3 
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reported that approximately 63% of patients with MDD 
and 85% of patients with chronic/double depression (ie, an 
MDD episode on top of dysthymia) entering clinical trials 
had severe QoL impairments.
Several studies have shown that impairments in QoL and 
functioning often persist beyond the clinical resolution of 
depressive symptoms,4 placing patients at an increased risk 
of relapse and leading to higher direct and indirect costs.5 
Notably, the severity of depressive symptoms has been found 
to explain only partially the impairment of QoL.3,4,6–8 This 
suggests that assessing depressive symptoms alone may not 
be sufficient to measure the success of MDD interventions.7 
There is thus a growing interest in complementing traditional 
symptom measures with additional QoL measures when 
evaluating treatment effectiveness.8,9
Selective serotonin reuptake inhibitors (SSRIs) and 
serotonin–norepinephrine reuptake inhibitors (SNRIs) are 
two classes of antidepressants with a better safety profile 
than older treatments, such as the tricyclic antidepressants, 
or the monoamine oxidase inhibitors.10–12 SSRIs and SNRIs 
are also recommended as first-line treatments for MDD by 
several international guidelines, such as those issued by the 
American Psychiatric Association,10 the British Association 
of Psychopharmacology,11 and the Canadian Network for 
Mood and Anxiety Treatments,12 for example.
While treatment for MDD has been shown to improve 
QoL,8 there is scant available evidence on the comparative 
effectiveness of SNRIs and SSRIs that is based on a formal 
assessment of QoL outcomes. The evidence on their com-
parative effectiveness in terms of symptom improvement is 
also limited and inconclusive.13–16 Nevertheless, emerging 
evidence suggests that SNRIs, including duloxetine, may 
have additional advantages for patients with concurrent 
pain and depression.13,14,17 Depression and pain are com-
mon comorbidities.18 Previous research has shown that the 
coexistence of these two conditions greatly impacts clinical 
outcomes, functioning, and QoL.19 It has been suggested that 
the dual action of SNRIs may be more effective than those 
that inhibit only one monoamine, at least for patients suffer-
ing from both depression and pain,13,14,17 given the hypothesis 
that the pathophysiology of both conditions involves an 
imbalance of serotonin and norepinephrine.18
Duloxetine hydrochloride is a potent and relatively bal-
anced inhibitor of serotonin and norepinephrine reuptake.20 
It has been approved for the management of MDD, gener-
alized anxiety disorder, fibromyalgia, diabetic peripheral 
neuropathic pain, and chronic musculoskeletal pain in the 
United States, and for some or all of these indications in 
many countries worldwide. In line with these indications, 
the findings from clinical trials have shown that treatment 
with duloxetine improves pain and that this further helps to 
improve the outcomes of depression.21–23 Such findings have 
been poorly documented for the SSRIs however.24–26
Using data from a 6-month prospective observational 
study conducted mostly in East Asia, the Middle East, and 
Mexico, this post hoc analysis aimed at examining the com-
parative effectiveness of duloxetine versus an SSRI on QoL 
in the treatment of MDD in a naturalistic clinical setting in 
non-Western countries. In addition, this study examined the 
impact of pain on the QoL outcomes. It examined whether 
the comparative effectiveness of duloxetine versus an SSRI 
differ between patients with and without painful physical 
symptoms (PPSs) at baseline; and whether baseline pain 
severity influences QoL improvements, and if so, whether 
this association varies with the type of treatment.
Patients and methods
study design
Data for this post hoc analysis were taken from a 6-month, 
international, prospective, noninterventional, observational 
study, primarily designed to examine treatment-emergent 
sexual dysfunction (TESD) and other treatment outcomes 
among patients with MDD who were treated with either an 
SSRI or an SNRI in actual clinical practice. A total of 1,647 
patients were enrolled at 88 sites between November 15, 
2007 and November 28, 2008. Of these, 1,549 patients 
were classified as “sexually active patients without sexual 
dysfunction at study entry” and were included in the study. 
The patients were drawn from the following regions and 
countries across the globe: East Asia (People’s Republic 
of China [n=205; 13.2%], Hong Kong [n=18; 1.2%], 
Malaysia [n=33; 2.1%], the Philippines [n=113; 7.3%], 
Taiwan [n=199; 12.8%], Thailand [n=17; 1.1%], and 
Singapore [n=2; 0.1%]), the Middle East (Saudi Arabia 
[n=179; 11.6%] and United Arab Emirates [n=135; 8.7%]), 
Mexico (n=591; 38.2%), and other regions (Israel [n=9; 
0.6%] and Austria [n=48; 3.1%]). This study followed the 
ethical standards of responsible local committees and the 
regulations of the participating countries, and was conducted 
in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki and are consistent 
with Good Clinical Practice where applicable to a study of 
this nature. Ethical Review Board approval was obtained 
in each of the 12 participating countries as required for 
observational studies wherever required by local law. All 
patients provided written informed consent for the  provision 
and collection of the data. Further details of the study design 
have been published elsewhere.27,28
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study population
Patients (outpatients) were eligible to participate in the study 
if they met the following inclusion criteria: 1) presenting 
with an episode of MDD within the normal course of care, 
with MDD diagnosed according to the International Statisti-
cal Classification of Diseases 10th revision29 or Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition text 
revision30 criteria; 2) at least moderately depressed, defined 
by the Clinical Global Impression of Severity (CGI-S) (with a 
score of 4);31 3) initiating or switching to any available SSRI 
or SNRI antidepressant in any of the participating countries, in 
accordance with a treating psychiatrist’s discretion; 4) at least 
18 years of age; 5) sexually active (with partner or autoerotic 
activity, including during the 2 weeks prior to study entry) 
without sexual dysfunction, as defined by Arizona Sexual 
Experience Scale;32 6) not participating in another currently 
ongoing study; and 7) providing consent to release data. The 
study excluded the patients who had: 1) a history of treatment-
resistant depression (defined as failure to respond to treatment 
with two different antidepressants from different classes at 
therapeutic doses for 4 weeks33); 2) a past or current diag-
nosis of schizophrenia, schizophreniform or schizoaffective 
disorder, bipolar disorder, dysthymia, mental retardation, or 
dementia; or 3) received any antidepressant within 1 week 
(1 month for fluoxetine) prior to study entry, with the exception 
of patients receiving an ineffective treatment for whom the 
immediate switch to an SSRI or SNRI antidepressant was con-
sidered to be the best treatment option. Patients who changed 
or discontinued medication after entry remained in the study, 
unless lost to follow-up or consent was withdrawn.
study therapy
Patients were prescribed any commercially available SSRI or 
SNRI in accordance with each country’s approved labels and 
at the discretion of the participating psychiatrist. Treatment 
decisions were made solely at the discretion of the treating 
psychiatrist, and were independent of study participation. 
Patients were not required to continue taking the medication 
initiated at baseline. Changes in medication and dosing as 
well as use of concomitant medications and nonpharmaco-
logical therapies for the treatment of depression were possible 
at any time as determined by the treating psychiatrist.
This analysis included only those patients who initiated 
either duloxetine (duloxetine cohort) or an SSRI (SSRI 
cohort), both as monotherapy at baseline.
Data collection and outcome assessment
Data collection for the study occurred during visits within 
the normal course of care. The routine outpatient visit at 
which patients were enrolled served as the time for baseline 
data collection. Subsequent data collection was targeted at 
week 8, week 16, and week 24 following the baseline visit. 
Patient demographics and clinical history were recorded at 
the baseline assessment.
Patient perception of QoL was assessed at each visit 
using the EuroQoL-5 Dimensions (EQ-5D), a patient self-
rated, generic, QoL measure. This instrument has five items 
(mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression), each of which is scored on a scale from 1 
(no problems) to 3 (extreme problems). Given that there are no 
single representative EQ-5D tariffs or country-specific tariffs 
for all countries included in this analysis, the commonly used 
UK population tariff was applied to the EQ-5D data to calcu-
late the utility score.34 The EQ-5D questionnaire also includes 
a visual analog scale (EQ-VAS) on which patients were asked 
to rate their current overall health that day on a scale from 
0 (worst imaginable health state) to 100 (best imaginable 
health state), thus providing an overall “health state” score. 
This study focuses on the levels of QoL assessed by the EQ-5D 
utility score as they are more comprehensive, and comple-
ments these with additional results from the EQ-VAS.
Clinical severity of depression was also assessed by the 
treating psychiatrists using the CGI-S scale31 and self-rated 
by patients using the 16-item Quick Inventory of Depressive 
Symptomatology Self-Report (QIDS-SR
16
).35 In addition, 
depression-related pain severity was measured using the 
pain-related items of Somatic Symptom Inventory (SSI), 
which included abdominal pain, lower back pain, joint pain, 
neck pain, pain in the heart or chest, headaches, and muscular 
soreness.36 PPS status was also assessed as painful physical 
symptom negative (PPS-) or positive (PPS+); PPS+ was 
defined as a mean score of 2 for the seven pain-related 
items of the SSI.
statistical analysis
This study included a total of 1,332 patients who 1) initiated 
either duloxetine or an SSRI as monotherapy at baseline for 
the treatment of MDD, and 2) who did not have missing 
data on the QIDS-SR
16
 score at baseline with at least one 
assessable QIDS-SR
16
 score during follow-up (n=556 in 
the duloxetine group and n=776 in the SSRI group). This 
study analyzed the patient observations up to the point 
where their initial medications were discontinued. Of the 
1,332 patients, 78.7% (n=1,048) were available at 24 weeks 
(n=443 [79.7%] in the duloxetine group and n=605 [78.0%] 
in the SSRI group).
Baseline patient characteristics as well as outcomes 
at each visit by treatment were described and compared 
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using the chi-square test (for categorical variables) and 
Mann–Whitney test (for continuous variables).
The mean levels (raw values) of QoL at each visit by 
treatment in the overall sample as well as in the subgroup of 
PPS+ and PPS- patients, respectively, were also described 
and compared using the Mann–Whitney test. The effect sizes 
were also calculated using Cohen’s d (ie, the difference in 
mean values divided by a standard deviation [SD])37 for the 
differences in the levels of QoL between the two treatment 
cohorts at each visit.
Adjusted mixed effects modeling with repeated measures 
(MMRM) analysis was used to compare the levels of QoL 
(EQ-VAS and EQ-5D) during follow-up between the two 
treatment cohorts. The unstructured covariance pattern was 
used to take into account within-patient correlation. These 
models were adjusted for age, sex, region, SSI-pain score at 
baseline, the baseline value of the outcome modeled, and visit 
number. In addition, the following variables were included 
for further adjustment if they appeared to be significant 
(P0.1) in simple regressions: independent living (living in 
his/her own house), living with a spouse/partner, employment 
level, had MDD episodes in the 24 months prior to baseline, 
MDD hospitalizations in the 24 months prior to baseline, 
number of significant preexisting comorbidities, CGI-S 
and QIDS-SR
16
 scores at baseline, and the interaction term 
between time (visit number) and treatment.
These analyses were repeated for subgroups of PPS+ 
and PPS- patients, respectively, to examine whether the 
comparative effectiveness of duloxetine versus an SSRI differ 
between PPS+ and PPS- patients. Similarly, these analyses 
were also repeated for subgroups of patients treated with 
duloxetine or an SSRI, respectively, to examine whether an 
association between baseline pain severity and QoL during 
follow-up varies with the type of treatment. Treatment-
related variables (ie, treatment and its interaction with time) 
were excluded in the latter subgroup analyses by treatment 
cohorts. All statistical analyses were performed using SAS 
version 9.1 for Windows (SAS Institute, Cary, NC, USA).
Results
Patient characteristics at study entry
Of the 1,332 patients included in this analysis, 556 patients 
(41.7%) initiated duloxetine, and 776 patients (58.3%) initi-
ated an SSRI antidepressant at baseline. The most common 
SSRIs prescribed at baseline were paroxetine (24.5%), escit-
alopram (23.7%), sertraline (21.1%), and fluoxetine (19.7%). 
The median daily doses of these medications at baseline were 
20.0 mg/day for paroxetine, 10.0 mg/day for escitalopram, 
50.0 mg/day for sertraline, 20.0 mg/day for fluoxetine, and 
60.0 mg/day for duloxetine.
Overall, the mean (SD) age of these patients was 38.0 
(10.5) years and 56.5% were female. More than one-third of 
the patients were from Mexico (n=562, 42.2%), followed by 
East Asia (n=455, 34.2%), the Middle East (n=275, 20.7%), 
and other countries (ie, Israel and Austria; n=40, 3.0%). 
In addition, more than half of the patients (n=685, 51.5%) 
were PPS+ at baseline (58.5% in the duloxetine cohort and 
46.5% in the SSRI cohort, P0.001).
Table 1 summarizes the baseline patient characteristics by 
treatment cohort. Although the mean age of the patients was 
similar between the two cohorts, the SSRI cohort had a higher 
proportion of females, patients from Mexico, patients living 
in their own apartment or house, and patients having lower 
education attainment, compared to the duloxetine cohort. 
Nevertheless, disease severity (CGI-S and QIDS-SR
16
) was 
similar between the two cohorts, whereas the mean SSI-pain 
score at baseline was higher in the duloxetine cohort than in 
the SSRI cohort (P0.001).
improvement in Qol by treatment 
cohort
Table 2 demonstrates the levels of QoL (raw means), as 
measured by EQ-5D and additional EQ-VAS, at baseline 
and at 24 weeks by treatment cohort. There were no statisti-
cally significant differences in the levels of QoL at baseline 
between the two treatment cohorts. The mean EQ-5D score 
at baseline was 0.46 (SD =0.32) in the duloxetine cohort and 
0.47 (SD =0.33) in the SSRI cohort (P=0.066). Similarly, the 
mean EQ-VAS score at baseline was 43.4 (SD =24.4) in the 
duloxetine cohort and 43.0 (SD =26.9) in the SSRI cohort 
(P=0.960). The mean levels of QoL at baseline were also 
similar between the two cohorts in each subgroup of PPS+ 
and PPS- patients, respectively, although the level of QoL 
was generally higher in PPS– patients.
Despite similar levels of QoL at baseline between the 
two treatment cohorts, duloxetine-treated patients achieved 
greater levels of QoL throughout the follow-up period, com-
pared to SSRI-treated patients. The mean EQ-5D score at 
24 weeks was 0.95 (SD =0.11) in the duloxetine cohort and 
0.90 (SD =0.16) in the SSRI cohort (P0.001). A similar 
pattern was also observed with the EQ-VAS results (75.6 
[SD =34.0] in the duloxetine cohort versus 69.0 [SD =32.8] 
in the SSRI cohort, P0.001). In addition, duloxetine-treated 
patients achieved greater levels of QoL than SSRI-treated 
patients in each subgroup of PPS+ and PPS- patients, respec-
tively. Notably, the difference in the levels of QoL between 
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the two treatment cohorts at 24 weeks appeared to be greater 
in PPS+ patients than in PPS- patients. The effect size of this 
treatment difference in terms of EQ-5D scores was 0.59 in 
PPS+ patients but 0.25 in PPS- patients. Although, a similar 
pattern was observed with EQ-VAS scores, the differences 
in the effect sizes between PPS+ (0.23) and PPS- patients 
(0.19) were rather modest.
The superiority of duloxetine over SSRIs in terms of 
QoL improvement was maintained even when the baseline 
differences between the two treatment cohorts were adjusted 
for (Figure 1). Given the interaction term between time and 
treatment included in the MMRM models (Tables 3 and 4), 
the interpretation of the coefficients of treatment, time 
and their interaction was not straightforward. Therefore, 
Table 1 Baseline patient characteristics by treatment cohorts
Baseline characteristic Duloxetine (n=556) SSRI (n=776) P-value
Age, mean (sD), years 38.2 (10.2) 37.9 (10.7) 0.539
Female, % 51.8 59.8 0.004
region, % 0.001
Mexico 29.1 51.5
east Asia 41.4 29.0
The Middle east 27.3 15.9
Others 2.2 3.6
Age at first symptoms of MDD, mean (SD), years 34.3 (10.6) 33.3 (11.6) 0.078
BMi (kg/m2), mean (sD) 24.6 (4.4) 24.8 (4.3) 0.277
living with a spouse/partner, % 69.9 69.7 0.948
independent living (living in his/her own apartment or house), % 12.4 19.3 0.001
educational attainment, % 0.020
 Primary school 6.3 9.7
secondary school/occupational program 42.3 45.2
 University 51.4 45.1
employment status, % 0.057
Full time 57.0 54.5
economically inactive 22.8 28.4
Unemployed/part-time 20.1 17.1
cgi-s, mean (sD) 4.5 (0.7) 4.6 (0.7) 0.292
QiDs-sr16, mean (sD) 14.2 (4.6) 14.5 (5.0) 0.356
ssi-pain, mean (sD) 15.2 (5.1) 13.8 (5.0) 0.001
had MDD episodes in the past 24 months, % 66.2 65.3 0.747
number of comorbidities, % 0.177
0 77.0 72.5
1 17.5 21.2
2+ 5.4 6.2
Any treatments/therapies for depression in the past 24 months, % 42.6 44.2 0.568
Painful physical symptoms, % 58.5 46.5 0.001
Abbreviations: BMi, body mass index; cgi-s, clinical global impressions of severity; MDD, major depressive disorder; QiDs-sr16, 16-item Quick inventory of Depressive 
symptomatology self-report; sD, standard deviation; ssi-pain, somatic symptom inventory; ssri, selective serotonin reuptake inhibitor.
Table 2 Mean levels (raw values) of Qol at baseline and at 24 weeks by treatment cohorts with and without PPs at baseline
Outcome Total PPS+ PPS-
Duloxetine SSRI Effect sizesa Duloxetine SSRI Effect sizesa Duloxetine SSRI Effect sizesa
EQ-5D
At baseline 0.46 (0.32) 0.47 (0.33) -0.03 0.37 (0.33) 0.40 (0.34) -0.09 0.58 (0.26) 0.54 (0.31) 0.14
At week 24 0.95 (0.11)b 0.90 (0.16) 0.35 0.95 (0.10)b 0.86 (0.19) 0.59 0.95 (0.12)b 0.92 (0.12) 0.25
EQ-VAS
At baseline 43.39 (24.36) 42.99 (26.94) 0.02 40.77 (24.23) 39.48 (27.25) 0.05 47.07 (24.11) 46.02 (26.36) 0.04
At week 24 75.64 (34.02)b 69.02 (32.79) 0.20 74.88 (34.94)b 66.88 (33.28) 0.23 76.75 (32.69)b 70.62 (32.38) 0.19
Notes: aThese show effect sizes of Qol differences between treatment cohorts. bP0.05 for all comparisons of outcomes between the duloxetine cohort and the ssri 
cohort in the overall sample, PPs+ patients, and PPs- patients, respectively.
Abbreviations: eQ-VAs, euroQol-Visual Analog scale; eQ-5D, euroQol-5 Dimensions; PPs, painful physical symptoms; Qol, quality of life; ssri, selective serotonin 
reuptake inhibitor.
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the (adjusted) mean levels of QoL (ie, least squares means) 
at each postbaseline visit by treatment cohorts were further 
estimated and presented in Figure 1. The MMRM results 
also showed that duloxetine-treated patients achieved higher 
levels of QoL (both EQ-5D and EQ-VAS), compared to 
SSRI-treated patients, throughout follow-up (P0.01 
for all treatment comparisons at each postbaseline visit). 
At 24 weeks, the estimated mean EQ-5D score was 0.90 
(standard error [SE] =0.01) in the duloxetine cohort, which 
was higher than that of 0.83 (SE =0.01) in the SSRI cohort 
(P0.001). Similarly, the estimated mean EQ-VAS score 
was 71.9 (SE =1.8) in the duloxetine cohort and 65.2 
(SE =1.7) in the SSRI cohort (P0.001). Consistent with 
the descriptive results, the difference in the levels of QoL at 
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Figure 1 The estimated mean levels of Qol during follow-up by treatment cohorts.
Notes: (A) eQ-5D scores by treatment cohorts. (B) eQ-VAs scores by treatment cohorts. P0.05 for all comparisons between the duloxetine cohort and the ssri cohort 
at each postbaseline visit. aThe baseline scores are raw mean values.
Abbreviations: ssri, selective serotonin reuptake inhibitor; Qol, quality of life; eQ-5D, euroQol-5 Dimensions; eQ-VAs, euroQol-Visual Analog scale.
Table 3 The results of MMrM analyses: factors associated with eQ-5D scores during follow-up
Parameter Parameter estimate Standard error P-value
intercept 0.850 0.030 0.001
Age -0.001 0.000 0.095
Female (versus male) -0.022 0.008 0.009
region (versus east Asia)
Mexico 0.025 0.010 0.009
The Middle east -0.028 0.012 0.019
Others -0.038 0.026 0.140
employment (versus full time)
economically inactive -0.019 0.009 0.048
Unemployed/part-time -0.013 0.011 0.236
not living in his/her own house 0.023 0.010 0.029
eQ-5D index at baseline 0.087 0.015 0.001
QiDs-sr16 score at baseline -0.002 0.001 0.107
ssi-pain score at baseline -0.004 0.001 0.001
comorbidities (versus none)
1 -0.034 0.010 0.001
2+ -0.113 0.018 0.001
had MDD episodes in the 24 months prior to baseline -0.021 0.008 0.008
Duloxetine (versus ssri) 0.034 0.011 0.002
Weeks (versus week 8)
Week 16 0.072 0.007 0.001
Week 24 0.117 0.008 0.001
Weeks × treat
Duloxetine at week 16 0.027 0.011 0.012
Duloxetine at week 24 0.035 0.012 0.003
Abbreviations: eQ-5D, euroQol-5 Dimensions; QiDs-sr16, 16-item Quick inventory of Depressive symptomatology self-report; ssri, selective serotonin reuptake inhibitor; 
MMrM, mixed effects modeling with repeated measures; MDD, major depressive disorder; ssi-pain, somatic symptom inventory; Qol, quality of life.
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24 weeks between the two treatment cohorts was greater in 
the subgroup of PPS+ patients than in that of PPS- patients 
(Figure 2).
Notably, the SSI-pain score at baseline was signifi-
cantly associated with poorer QoL during follow-up, as 
measured by EQ-5D (P0.001; P=0.068 for the associa-
tion with EQ-VAS). This analysis was repeated in each 
subgroup of patients treated with duloxetine or an SSRI, 
respectively. While this association between pain severity 
and QoL, as measured by EQ-5D, was also observed in 
SSRI-treated patients (P0.001), this relationship was 
not retained in duloxetine-treated patients (P=0.479) (data 
not shown).
Discussion
This post hoc analysis of data from a 6-month, prospec-
tive, observational study conducted mostly in East Asia, 
the Middle East, and Mexico shows that although both 
Table 4 The results of MMrM analyses: factors associated with eQ-VAs scores during follow-up
Parameter Parameter estimate Standard error P-value
intercept 18.371 5.498 0.001
Age -0.164 0.061 0.007
Female (versus male) -1.022 1.302 0.433
region (versus east Asia)
Mexico -5.353 1.539 0.001
The Middle east -16.048 1.813 0.001
Others -8.566 4.161 0.040
cgi-s score at baseline 4.190 0.954 0.001
eQ-VAs score at baseline 0.733 0.025 0.001
ssi-pain score at baseline 0.237 0.129 0.068
comorbidities (versus none)
1 -4.181 1.680 0.013
2+ -5.546 2.981 0.063
had MDD episodes in the 24 months prior to baseline -1.071 1.328 0.420
Duloxetine (versus ssri) 3.953 1.322 0.003
Weeks (versus week 8)
Week 16 6.741 0.586 0.001
Week 24 10.656 0.719 0.001
Weeks × treat
Duloxetine at week 16 1.456 0.901 0.106
Duloxetine at week 24 2.793 1.106 0.012
Abbreviations: eQ-VAs, euroQol-Visual Analog scale; cgi-s, clinical global impressions of severity; ssri, selective serotonin reuptake inhibitor; MMrM, mixed effects 
modeling with repeated measures; MDD, major depressive disorder; ssi-pain, somatic symptom inventory; Qol, quality of life.
Figure 2 The estimated mean levels of Qol during follow-up by treatment cohorts in patients with and without PPs at baseline.
Notes: (A) eQ-5D scores by treatment cohorts. (B) eQ-VAs scores by treatment cohorts. P0.05 for all comparisons between the duloxetine cohort and the ssri cohort 
at 24 weeks in both PPs+ and PPs- patients, respectively. aThe baseline scores are raw mean values.
Abbreviations: PPs, painful physical symptoms; ssri, selective serotonin reuptake inhibitor; Qol, quality of life; eQ-5D, euroQol-5 Dimensions; eQ-VAs, euroQol-Visual 
Analog scale.
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duloxetine and SSRIs improve patient’s QoL in the treatment 
of MDD, the effect of duloxetine is likely greater than that 
of SSRIs in this population. These findings are consistent 
with other treatment outcomes.38,39 Specifically, the mean 
EQ-5D score increased from 0.46 at study entry to 0.90 
(estimated mean) at 24 weeks in duloxetine-treated patients 
and from 0.47 at study entry to 0.83 (estimated mean) at 24 
weeks in SSRI-treated patients. The difference in the QoL 
at 24 weeks between the two treatment cohorts appeared to 
be more pronounced in patients with PPSs at baseline than 
in patients without such symptoms at baseline. Neverthe-
less, overall, both treatment groups achieved a level of QoL 
very close to that of general population, which ranges from 
0.833 in Zimbabwe (Harare district) to 0.958 in South Korea, 
among 15 countries/regions providing population data with 
country-specific tariffs.40 In addition, our results confirm a 
negative association between the severity of pain at baseline 
and levels of QoL during follow-up, as measured by EQ-5D. 
Notably, this relationship was not observed in the subgroup 
of patients treated with duloxetine, but clearly observed in 
those treated with SSRIs.
The World Health Organization defines health-related 
QoL as an:
Individual’s perception of their position in life [...] It is 
a broad ranging concept affected in a complex way by 
the person’s physical health, psychological state, level of 
independence, social relationships, personal beliefs and their 
relationship to salient features of their environment.41
QoL is increasingly recognized as an important mea-
sure of health in medical and psychiatric patients.7,42 Not 
surprisingly, the baseline EQ-5D scores indicate that, on 
average, our study patients had moderately impaired QoL 
at baseline, according to a recent review on utility val-
ues of depressed patients.43 Our study also suggests that 
treatment with antidepressants can improve the level of 
QoL, helping patients return to a “normal level” of QoL. 
However, despite increasing awareness and recognition of 
QoL as an important treatment outcome, the use of QoL 
as an outcome measure has been very limited in clinical 
trials that assess the comparative effectiveness of different 
treatments for MDD.
Instead, several studies have examined the comparative 
effectiveness of SNRIs including duloxetine and SSRIs in 
terms of symptom improvement, but the superiority of SNRIs 
over SSRIs has not been well established in the literature. 
Some studies have suggested that dual acting monoamine 
inhibitors such as the SNRIs may be more efficacious than 
those that work by inhibiting only one monoamine,13,14 while 
others have reported no significant or clinically meaning-
ful differences between the two classes of medications.15,44 
A recent systematic review also reported no difference in 
efficacy between duloxetine and SSRIs.16
Nevertheless, emerging empirical evidence suggests that 
“dual-action drugs” like the SNRIs including duloxetine 
may have additional advantages for patients with concurrent 
pain and depression.13,14,17 Notably, approximately 51% of 
patients in our study suffered from PPSs at baseline (59% 
in the duloxetine cohort and 47% in the SSRI cohort). More 
importantly, the findings of both descriptive and regression 
analyses confirmed this additional advantage of duloxetine 
over SSRIs in patients with PPSs at baseline. The effect size 
of the difference in EQ-5D scores at 24 weeks between the 
two treatment cohorts was 0.59 (“medium” effect differ-
ence) in patients with PPSs at baseline but 0.25 (“small” 
effect difference) in patients without PPSs at baseline.37 
A similar pattern was also observed even after baseline 
patient characteristics were adjusted for in the multiple 
regressions.
In this light, the subgroup analyses by treatment cohorts 
also revealed some interesting findings. Our study found 
a negative association between baseline pain severity and 
QoL during follow-up. However, patients taking duloxetine 
achieved the same level of QoL independently of pain sever-
ity at baseline, whereas this was not the case for the subgroup 
of patients taking SSRIs. That is, patients taking SSRIs who 
had a higher level of pain severity at baseline did not achieve 
the same level of QoL as those taking SSRIs who had a lower 
level of pain severity at baseline, confirming the negative 
impact of pain on improvement of QoL in this cohort (but 
not in the duloxetine cohort). Taken together, our findings 
reconfirm the importance of controlling pain symptoms in 
the treatment of depression and the potential advantages of 
duloxetine over SSRIs, at least for patients with concurrent 
pain and depression.
These results should be interpreted in the context of the 
following study limitations. First, given the observational 
design of this study, our findings do not imply causal rela-
tionships. Although we employed statistical modeling tech-
niques to limit potential sources of bias between treatment 
groups at study entry, the statistical techniques used cannot 
completely eliminate the impact of imbalances between 
treatment groups. Secondly, as the primary objective of this 
observational study was to assess the frequency of TESD 
in the treatment of MDD, the study included only those 
patients who were sexually active without sexual dysfunction 
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at baseline. Sexual dysfunction has been reported to be 
two to three times more prevalent in patients with depression 
compared to the general population,45,46 and thus our find-
ings may not be immediately generalizable to patients with 
MDD as a whole. Further research is warranted to examine 
whether these findings can be replicated in MDD patients 
without such inclusion/exclusion criteria. Finally, given that 
there are no single representative EQ-5D tariffs or country-
specific tariffs for all countries included in our analysis, we 
applied the commonly used UK tariff to the EQ-5D data to 
calculate utility scores.34 While there is evidence that different 
populations value health states differently (including racial/
ethnic differences),47 the EQ-5D has been shown to be useful 
for assessing QoL in patients with MDD.48
Conclusion
Patients treated with duloxetine achieved higher levels of 
health-related QoL compared to those treated with SSRIs 
for the management of MDD in actual clinical practice 
settings mostly in East Asia, the Middle East, and Mexico. 
The superiority of duloxetine over SSRIs on QoL outcomes 
appeared to be more pronounced in patients with PPSs than 
in patients without such symptoms at baseline. In addition, 
we also found that patients taking duloxetine, unlike patients 
taking SSRIs, achieved the same level of QoL independently 
of their pain severity at baseline. This suggests that the nega-
tive impact of pain on QoL may be mitigated somewhat by 
treatment with duloxetine, which may in turn help explain 
the higher level of QoL found for duloxetine-treated patients. 
However, given that our study included only those patients 
who were sexually active without sexual dysfunction at 
baseline, these findings may not be immediately generaliz-
able to patients with MDD as a whole and should therefore 
be validated with MDD patients without such inclusion/
exclusion criteria.
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